A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases ...

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

Adding an anti-obesity medication just one month after behavioral therapy begins—rather than waiting the currently ...

As the old saying goes, “an ounce of prevention is worth a pound of cure,” and in my decades of experience in healthcare that ...

Adding an anti-obesity medication just one month after behavioral therapy begins-rather than waiting the currently recommended six months-can more than double weight loss for patients who struggle ...

In countless reports and studies, obesity is often reduced to just a number: 42% of adults in the U.S. have obesity, ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

State lawmakers are considering expanding the types of obesity treatments covered by Nevada Medicaid, including approving ...

A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases in life expectancy and disease-free years while generating a ...